| |
Recovery
|
Combined Endpoint
|
p-value
|
OR (CI 95%)
|
|---|
|
(n = 34)
|
(n = 11)
|
|---|
|
Age (years)
|
32.8 ± 14.7
|
48.4 ± 13.2
|
0.05
| |
|
male
|
24 (71)
|
5 (45)
|
0.16
|
2.9 (0.86–1.25)
|
|
Clinical Presentation
| | | | |
|
Chest Pain
|
21 (62)
|
5 (45)
|
0.49
|
0.5 (0.13–1.83)
|
|
Palpitations
|
3 (9)
|
4 (36)
|
0.05
|
5.9 (1.27–26.33)
|
|
Fatigue
|
25 (74)
|
8 (73)
|
0.99
|
0.9(0.24–3.39)
|
|
Dyspnoea (NYHA Class)
| | | | |
|
III
|
8 (24)
|
6 (55)
|
0.07
|
3.9 (1.04–16.96)
|
|
IV
|
4 (12)
|
2 (18)
|
0.62
|
1.7 (0.28–8.62)
|
|
Blood Testing
|
|
Troponin (ng/ml)
|
363 ± 8135
|
103 ± 143
|
0.19
| |
|
BNP (pg/ml)
|
4046 ± 8135
|
3636 ± 2497
|
0.91
| |
|
EMB Results
| | | | |
|
Imflammation on EMB
|
15 (54)
|
5 (50)
|
0.99
|
1.0 (0.29–4.21)
|
|
Presence of virus genome
|
13 (52)
|
8 (73)
|
0.29
|
2.5 (0.57–9.91)
|
|
CMR Parameters
|
|
LVEF (%)
|
44 ± 13
|
33 ± 14
|
0.02
| |
|
LVEF <30%
|
7 (21)
|
7 (64)
|
0.02
|
6.8 (1.56–24.12)
|
|
Presence of LGE
|
26 (76)
|
10 (91)
|
0.25
|
4.2 (0.62–49.34)
|
|
T2 Ratio >1.9
|
14 (41)
|
5 (45)
|
0.99
|
1.2 (0.31–4.09)
|
|
Global T2 Time (ms)
|
66.8 ± 4.9
|
71.8 ± 5.7
|
0.01
| |
|
Global T2 Time, >2SD
|
12 (35)
|
8 (73)
|
0.04
|
4.9 (1.1–18.9)
|
|
Global T2 Time, >4SD
|
4 (12)
|
5 (45)
|
0.02
|
6.3 (1.2–24.9)
|
|
Fraction with T2 Time >80 ms (%)
|
15.1 ± 8.7
|
27.5 ± 14.9
|
0.03
| |
|
Fraction with T2 Time >80 ms, >2SD
|
23 (68)
|
10 (91)
|
0.24
|
4.7 (0.7–56.2)
|
|
Fraction with T2 Time >80 ms, >4SD
|
12 (35)
|
8 (73)
|
0.04
|
4.9 (1.1–18.9)
|
-
Abbreviations: Fraction >80 ms Percentage of myocardial fraction with T2 time >80 ms, BNP Brain Natriuretic Peptide, EMB Endomyocardial Biopsy, LVEF Left ventricular ejection fraction, LGE presence of Late Gadolinium Enhancement, T2w Imaging increased T2 ratio >1.9 (T2 weighted Imaging)
